Contributor Disclosures for Toxicity, Plants - Caladium, Dieffenbachia, and Philodendron
Role Name Disclosure Details
Author Christopher P Holstege, MD, Associate Professor of Emergency Medicine and Pediatrics, University of Virginia; Director, Division of Medical Toxicology, Center of Clinical Toxicology; Medical Director, Blue Ridge Poison Ctr, Associate Medical Toxicology Fellowship Director, VA Dept of Health Nothing to discloseDetails
Coauthor Tracey H Reilly, MD, Fellow, Division of Medical Toxicology, Department of Emergency Medicine, Blue Ridge Poison Center, University of Virginia Health System Nothing to discloseDetails
Coauthor Mark A Hostetler, MD, MPH, Assistant Professor of Pediatrics, University of Chicago; Chief, Section of Emergency Medicine, Department of Pediatrics, Medical Director of Pediatric Emergency Department, University of Chicago Children's Hospital Nothing to discloseDetails
Medical Editor Michael E Mullins, MD, Assistant Professor, Department of Emergency Medicine, Washington University School of Medicine Johnson & Johnson
Savient Pharmaceuticals
Details
Pharmacy Editor Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc Pfizer Inc
Avanir Pharma
Details
Managing Editor Jeffrey R Tucker, MD, Assistant Professor, Department of Pediatrics, Division of Emergency Medicine, University of Connecticut and Connecticut Children's Medical Center MerckDetails
CME Editor Daniel Rauch, MD, FAAP, Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine Baxter
Pfizer
Details
Chief Editor Maureen Strafford, MD, Arnold P Gold Foundation Associate Professor, Departments of Anesthesiology and Pediatrics, Tufts University and Tufts-New England Medical Center Nothing to discloseDetails






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Christopher P Holstege

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Off label or investigational use of medication









Contributor Disclosure


Contributor:
Contributor Disclosure:
Tracey H Reilly, Coauthor  The contributor discloses no conflict of interest. 









Contributor Disclosure


Contributor:
Contributor Disclosure:
Mark A Hostetler, Coauthor  The contributor discloses no conflict of interest. 






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Michael E Mullins

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Johnson & Johnson
stock ownershipNone 
Savient Pharmaceuticals
stock ownershipNone 
Off label or investigational use of medication






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Mary L Windle

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Pfizer Inc
StockInvestment from broker recommendation 
Avanir Pharma
StockInvestment from broker recommendation 
Off label or investigational use of medication






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Jeffrey R Tucker

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Merck
SalaryEmployment 
Off label or investigational use of medication






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Daniel Rauch

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Baxter
HonorariaConsulting 
Pfizer
HonorariaConsulting 
Off label or investigational use of medication
none









Contributor Disclosure


Contributor:
Contributor Disclosure:
Maureen Strafford, Chief Editor  The contributor discloses no conflict of interest.